Home
Companies
Zealand Pharma

Zealand Pharma

Company

Company Profile

Zealand Pharma is an international biotechnology company headquartered in Denmark that develops peptide-based and small-molecule medicines, with operations in Boston. It is listed on Nasdaq Copenhagen under the ticker ZEAL.

Website: https://www.zealandpharma.com
Headquarters: Soborg, Denmark
Founded: 1998
Stock Ticker: NASDAQCOPENHAGEN:ZEAL

Related News

New GLP-1 Competition, FDA Approval, and Genomic Atlases Advance Drug Development

Jun 15, 2026

At the ADA Scientific Sessions, Novo Nordisk's Wegovy pill surpassed 3 million prescriptions within five months, while Structure Therapeutics and AstraZeneca shared mid-stage GLP-1 data targeting a 2029 launch. The US FDA approved TRUQAP as the first targeted treatment for PTEN-deficient metastatic prostate cancer, reducing disease progression risk by 19% in the CAPItello-281 trial. Meanwhile, two major genomic atlas projects—a 4,098-genome infant gut bacteria catalog and Basecamp Research's Trillion Gene Atlas—aim to advance precision probiotics and AI-driven drug discovery, respectively.

Congenital Hyperinsulinism Pipeline Shows 4+ Active Players and Late-Stage Drug Candidates

Apr 18, 2026

The congenital hyperinsulinism pipeline includes 4+ active companies and 4+ therapies across clinical and nonclinical stages. Zealand Pharma advanced dasiglucagon in January 2026, while RZ358 is in Phase III evaluation.

Roche-Zealand Obesity Drug Petrelintide Shows 10.7% Weight Loss in Phase 2 Trial

Mar 06, 2026

Zealand Pharma's petrelintide achieved up to 10.7% average weight loss after 42 weeks in a 493-patient phase 2 trial, with placebo-like tolerability but lower efficacy than competing amylin drugs, causing Zealand shares to drop 34%.

Roche's Genentech Reports 22.5% Weight Loss in Phase II Trial of Obesity Drug CT-388

Mar 06, 2026

Genentech announced positive Phase II results for CT-388, a dual GLP-1/GIP receptor agonist, showing 22.5% placebo-adjusted weight loss at 48 weeks in people with obesity. The treatment was well-tolerated with low discontinuation rates.

Zealand Pharma Reports Strong Q4 2025 Results Driven by Roche Partnership

Mar 05, 2026

Zealand Pharma reported full-year 2025 revenue of DKK 9.2 billion, bolstered by a significant upfront payment from Roche. The company ended the year with DKK 15.1 billion in cash and set 2026 operating expense guidance between DKK 2.72 billion and DKK 3.3 billion.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07733089	A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period	RECRUITING	PHASE1
NCT07721597	A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity	RECRUITING	EARLY_PHASE1
NCT07682818	Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function	RECRUITING	PHASE1
NCT07589686	A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight	NOT_YET_RECRUITING	PHASE2
NCT07338214	Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations	COMPLETED	PHASE1
NCT07228403	Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome	ACTIVE_NOT_RECRUITING	PHASE3
NCT07197944	Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS	RECRUITING	PHASE3
NCT07076030	Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function	COMPLETED	PHASE1
NCT06926842	Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)	ACTIVE_NOT_RECRUITING	PHASE2
NCT06758583	A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide	COMPLETED	PHASE1